Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III studyCharles L Vogel, Marek Z Wojtukiewicz, Robert R Carroll, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseMelody A Cobleigh, Charles L Vogel, Debu Tripathy, et al.The Oncologist|November 25, 2004
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapyCharles L Vogel, Ronald H Yanagihara, Albert J Wood, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerCharles L Vogel, Melody A Cobleigh, Debu Tripathy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2023
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerCharles L Vogel, Melody A Cobleigh, Debu Tripathy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancerAlan M Keller, Robert G Mennel, Vassilis A Georgoulias, et al.Cancer Chemotherapy and Pharmacology|January 25, 2012
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerSandhya Girish, Manish Gupta, Bei Wang, et al.Seminars in Oncology|February 19, 2005
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert, Charles L Vogel, I Craig Henderson, et al.Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.Pageof 4